keyword
MENU ▼
Read by QxMD icon Read
search

meningococcal b vaccine

keyword
https://www.readbyqxmd.com/read/28100432/effectiveness-and-impact-of-a-reduced-infant-schedule-of-4cmenb-vaccine-against-group-b-meningococcal-disease-in-england-a-national-observational-cohort-study
#1
Sydel R Parikh, Nick J Andrews, Kazim Beebeejaun, Helen Campbell, Sonia Ribeiro, Charlotte Ward, Joanne M White, Ray Borrow, Mary E Ramsay, Shamez N Ladhani
BACKGROUND: In September, 2015, the UK became the first country to introduce the multicomponent group B meningococcal (MenB) vaccine (4CMenB, Bexsero) into a publicly funded national immunisation programme. A reduced two-dose priming schedule was offered to infants at 2 months and 4 months, alongside an opportunistic catch-up for 3 month and 4 month olds. 4CMenB was predicted to protect against 73-88% of MenB strains. We aimed to assess the effectiveness and impact of 4CMenB in vaccine-eligible infants in England...
December 3, 2016: Lancet
https://www.readbyqxmd.com/read/28099125/meningococcal-acwy-vaccine-uptake-and-awareness-among-student-freshers-enrolled-at-northern-ireland-universities
#2
Peter J A Moore, B Cherie Millar, John E Moore
A new MenACWY conjugate meningococcal vaccination programme was introduced in Northern Ireland (NI) in August 2015, for 13-18 year olds, as well as for first-time university entrants up to 25 years. This reflected the response made by Public Health England, due to the recent rapid increase of meningococcal group W (MenW) disease and on advice of the UK Joint Committee on Vaccination and Immunisation (JCVI). The aims of this study were to evaluate (i) the uptake of the MenACWY vaccine among first-time university students, (ii) vaccine and meningitis awareness, (iii) optimal communication modalities via a multidisciplinary team (MDT) model and (iv) current international vaccination policies relating to non-UK students...
January 18, 2017: International Journal of Adolescent Medicine and Health
https://www.readbyqxmd.com/read/28072958/-investigation-on-immunization-program-coverage-rate-and-its-safety-in-children-with-tuberous-sclerosis
#3
Y Gao, L P Zou, M N Zhang, L Y Pang, Y Y Wang, S F Ma, L L Huang
Objective: To investigate the status of immunization of National Immunization Program (NIP) and its adverse reaction rate in children with tuberous sclerosis. Method: Questionnaire survey was adopted to identify the vaccination coverage and its adverse events; 72 cases of children with tuberous sclerosis and 78 normal controls (healthy children completing age-appropriate NIP) admitted to Chinese People's Liberation Army General Hospital from December 2014 to November 2015 were involved into this study. Result: The age-appropriate NIP coverage rate of tuberous sclerosis was 36%(26/72)...
January 2, 2017: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://www.readbyqxmd.com/read/28038948/-immunisation-schedule-of-the-spanish-association-of-paediatrics-2017-recommendations
#4
David Moreno-Pérez, Francisco José Álvarez García, Javier Arístegui Fernández, María José Cilleruelo Ortega, José María Corretger Rauet, Nuria García Sánchez, Ángel Hernández Merino, Teresa Hernández-Sampelayo Matos, Manuel Merino Moína, Luis Ortigosa Del Castillo, Jesús Ruiz-Contreras
The Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV- AEP) annually publishes the immunisation schedule which, in our opinion, is considered optimal for children resident in Spain, taking into account the evidence available on current vaccines. Pneumococcal and varicella immunisation in early childhood is already included in all funded vaccines present in the regional immunisation programmes. Furthermore, this committee establishes recommendations on vaccines not included in official calendars (non-funded immunisations), such as rotavirus, meningococcal B, and meningococcal ACWY...
December 27, 2016: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
https://www.readbyqxmd.com/read/28029540/use-of-a-booster-dose-of-capsular-group-c-meningococcal-glycoconjugate-vaccine-to-demonstrate-immunologic-memory-in-children-primed-with-one-or-two-vaccine-doses-in-infancy
#5
David Pace, Ameneh Khatami, Simon Attard-Montalto, Merryn Voysey, Adam Finn, Saul N Faust, Paul T Heath, Ray Borrow, Matthew D Snape, Andrew J Pollard
BACKGROUND: Use of a polysaccharide vaccine challenge to demonstrate immunologic memory after priming with capsular group C meningococcal conjugate vaccines (MenCC) risks induction of immunologic hyporesponsiveness. For this reason, MenCC vaccines are now used as probes of immunologic memory, however, no studies have demonstrated their ability to distinguish primed from unprimed children. METHODS: This study was part of a randomised controlled trial investigating the immunogenicity of a booster dose of the combined Haemophilus influenzae type b and MenC-tetanus toxoid vaccine (Hib-MenC-TT) in infants receiving reduced dose MenCC vaccine priming schedules (one MenC-CRM/MenC-TT or two MenC-CRM vaccine doses) compared with an unprimed group...
October 28, 2016: Vaccine
https://www.readbyqxmd.com/read/28008331/a-meningococcal-outer-membrane-vesicle-vaccine-incorporating-genetically-attenuated-endotoxin-dissociates-inflammation-from-immunogenicity
#6
David J Dowling, Holly Sanders, Wing Ki Cheng, Sweta Joshi, Spencer Brightman, Ilana Bergelson, Carlo Pietrasanta, Simon D van Haren, Sandra van Amsterdam, Jeffrey Fernandez, Germie P J M van den Dobbelsteen, Ofer Levy
BACKGROUND: Group B Neisseria meningitidis, an endotoxin-producing Gram-negative bacterium, causes the highest incidence of group B meningococcus (MenB) disease in the first year of life. The Bexsero vaccine is indicated in Europe from 8 weeks of age. Endotoxin components of outer membrane vesicles (OMVs) or soluble lipopolysaccharide (LPS) represent a potential source of inflammation and residual reactogenicity. The purpose of this study was to compare novel candidate MenB vaccine formulations with licensed vaccines, including Bexsero, using age-specific human in vitro culture systems...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27960595/meningococcal-serogroup-b-vaccines-estimating-breadth-of-coverage
#7
Robert G K Donald, Julio Cesar Hawkins, Li Hao, Paul Liberator, Thomas R Jones, Shannon L Harris, John L Perez, Joseph J Eiden, Kathrin U Jansen, Annaliesa S Anderson
Neisseria meningitidis serogroup B (MenB) is an important cause of invasive meningococcal disease. The development of safe and effective vaccines with activity across the diversity of MenB strains has been challenging. While capsular polysaccharide conjugate vaccines have been highly successful in the prevention of disease due to meningococcal serogroups A, C, W, and Y, this approach has not been possible for MenB owing to the poor immunogenicity of the MenB capsular polysaccharide. Vaccines based on outer membrane vesicles have been successful in the prevention of invasive MenB disease caused by the single epidemic strain from which they were derived, but they do not confer broad protection against diverse MenB strains...
December 14, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27939054/concomitant-administration-of-a-fully-liquid-ready-to-use-dtap-ipv-hb-prp-t-hexavalent-vaccine-with-a-meningococcal-serogroup-c-conjugate-vaccine-in-infants
#8
Timo Vesikari, Ray Borrow, Xavier Da Costa, Patrick Richard, Cécile Eymin, Florence Boisnard, Stephen Lockhart
DTaP-IPV-HB-PRP-T or hexavalent vaccines are indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib). The present study evaluates the safety and immunogenicity of a ready-to-use hexavalent vaccine when co-administered with a meningococcal serogroup C conjugate (MenC) vaccine in infants. This was a phase III, open-label, randomised, multicentre study conducted in Finland...
January 11, 2017: Vaccine
https://www.readbyqxmd.com/read/27936105/serogroup-and-clonal-characterization-of-czech-invasive-neisseria-meningitidis-strains-isolated-from-1971-to-2015
#9
Zuzana Jandova, Martin Musilek, Zuzana Vackova, Jana Kozakova, Pavla Krizova
BACKGROUND: This study presents antigenic and genetic characteristics of Neisseria meningitidis strains recovered from invasive meningococcal disease (IMD) in the Czech Republic in 1971-2015. MATERIAL AND METHODS: A total of 1970 isolates from IMD, referred to the National Reference Laboratory for Meningococcal Infections in 1971-2015, were studied. All isolates were identified and characterized by conventional biochemical and serological tests. Most isolates (82...
2016: PloS One
https://www.readbyqxmd.com/read/27917091/vaccinating-patients-with-inflammatory-bowel-disease
#10
Jason Reich, Sharmeel Wasan, Francis A Farraye
Patients with inflammatory bowel disease (IBD) are not vaccinated at the same rate as general medical patients. IBD places patients at increased risk for developing vaccine-preventable illnesses, and this risk is further exacerbated by immunosuppressive therapy. Therefore, gastroenterologists should familiarize themselves with health maintenance measures pertaining to patients with IBD. This article highlights the vaccinations required for patients with IBD, especially those who are immunosuppressed: influenza; pneumococcal pneumonia; hepatitis A and B viruses; human papilloma virus; meningococcal disease; tetanus, diphtheria, and pertussis; measles, mumps, and rubella; varicella zoster; and herpes zoster...
September 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27912986/a-phase-iii-observer-blind-randomized-controlled-study-to-evaluate-the-immune-response-and-the-correlation-with-nasopharyngeal-carriage-after-immunization-of-university-students-with-a-quadrivalent-meningococcal-acwy-glycoconjugate-or-serogroup-b-meningococcal
#11
Robert C Read, Peter Dull, Xilian Bai, Kate Nolan, Jamie Findlow, Rohit Bazaz, Annett Kleinschmidt, Maggie McCarthy, Huajun Wang, Daniela Toneatto, Ray Borrow
BACKGROUND: University students have high rates of pharyngeal carriage of Neisseria meningitidis. Interruption of carriage acquisition is an important mechanism of vaccines for inducing herd protection. 4CMenB and MenACWY-CRM vaccines have been shown to be immunogenic against meningococcal serogroups B and ACWY respectively in younger age groups, and also to elicit a modest impact on meningococcal carriage in vaccinated students. However, vaccine responses in university students and the impact of serum bactericidal antibody (SBA) titers on meningococcal carriage are undetermined...
January 11, 2017: Vaccine
https://www.readbyqxmd.com/read/27884478/vaccine-provision-delivering-sustained-widespread-use
#12
Scott Preiss, Nathalie Garçon, Anthony L Cunningham, Richard Strugnell, Leonard R Friedland
The administration of a vaccine to a recipient is the final step in a development and production process that may have begun several decades earlier. Here we describe the scale and complexity of the processes that brings a candidate vaccine through clinical development to the recipient. These challenges include ensuring vaccine quality (between 100 and 500 different Quality Control tests are performed during production to continually assess safety, potency and purity); making decisions about optimal vaccine presentation (pre-filled syringes versus multi-dose vials) that affect capacity and supply; and the importance of maintaining the vaccine cold chain (most vaccines have stringent storage temperature requirements necessary to maintain activity and potency)...
December 20, 2016: Vaccine
https://www.readbyqxmd.com/read/27881489/kinetics-of-meningococcal-serogroup-c-specific-functional-antibody-levels-up-to-15-years-after-a-single-immunization-with-a-meningococcal-serogroup-c-conjugate-vaccine-during-adolescence
#13
Susanne P Stoof, Mariëtte B van Ravenhorst, Debbie M van Rooijen, Richarda M de Voer, Fiona R M van der Klis, Greet J Boland, Elisabeth A M Sanders, Guy A M Berbers, Peter F Teunis
BACKGROUND: Adolescent vaccination is now considered the key factor to offer direct protection against meningococcal disease but also to reduce carriage and transmission and in this way establish herd protection. This study estimated age-dependent patterns in functional meningococcal serogroup C (MenC) antibody kinetics after primary MenC conjugate (MenCC) vaccination in adolescents. METHODS: Serum samples (n=1676) were drawn between 2006-2011 from individuals aged 9-18 years at time of primary MenCC vaccination in 2002...
November 23, 2016: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/27869440/immunology-update-new-vaccines
#14
S Paul Starr
A new 9-valent human papillomavirus (HPV) vaccine is effective against more cancer-causing HPV types than previous vaccines. HPV vaccine series started with previous vaccines can be completed with the 9-valent vaccine. Two new influenza vaccines are available for adults 65 years and older: a high-dose vaccine and an enhanced adjuvant vaccine. These elicit stronger antibody responses than standard-dose vaccines. Current guidelines specify no preference for the new versus standard-dose vaccines. Two new group B meningococcal vaccines are intended for use during outbreaks and for patients with asplenia, complement deficiencies, frequent occupational meningococcus exposure, or for patients who desire protection from type B meningococcus...
November 2016: FP Essentials
https://www.readbyqxmd.com/read/27864913/human-secretory-igm-antibodies-activate-human-complement-and-offer-protection-at-mucosal-surface
#15
Terje E Michaelsen, Sidsel Emilsen, Randi H Sandin, Beathe Kiland Granerud, Diane Bratlie, Oistein Ihle, Inger Sandlie
IgM molecules circulate in serum as large polymers, mainly pentamers, which can be transported by the poly-Ig receptor (pIgR) across epithelial cells to mucosal surfaces and released as secretory IgM (SIgM). The mucosal SIgM molecules have non-covalently attached secretory component (SC), which is the extracellular part of pIgR which is cleaved from the epithelial cell membrane. Serum IgM antibodies do not contain SC, and have previously been shown to make a conformational change from "a star" to a "staple" conformation upon reaction with antigens on a cell surface, enabling them to activate complement...
November 16, 2016: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/27861618/meningococcal-carriage-among-adolescents-after-mass-meningococcal-c-conjugate-vaccination-campaigns-in-salvador-brazil
#16
Amélia Maria Pithon Borges Nunes, Guilherme Sousa Ribeiro, Ítalo Eustáquio Ferreira, Ana Rafaela Silva Simões Moura, Ridalva Dias Martins Felzemburgh, Ana Paula Silva de Lemos, Mitermayer Galvão Reis, José Cassio de Moraes, Leila Carvalho Campos
Neisseria meningitidis is a commensal bacterium of the human nasopharynx. In rare cases, it penetrates the mucosa, entering the blood stream and causing various forms of disease. Meningococcal conjugate vaccines can prevent invasive disease not only by direct effect in vaccinated individuals but also by herd protection, preventing acquisition of carriage, which interrupts transmission and leads to protection of unvaccinated persons. In 2010 in Salvador, Brazil, an outbreak of group C meningococcal disease led to a mass meningococcal serogroup C conjugate vaccination drive, targeting those <5 and 10-24 years of age...
2016: PloS One
https://www.readbyqxmd.com/read/27847367/serum-bactericidal-antibody-responses-of-adults-immunized-with-the-menb-4c-vaccine-against-genetically-diverse-serogroup-b-meningococci
#17
Serena Giuntini, Eduardo Lujan, Malick M Gibani, Christina Dold, Christine S Rollier, Andrew J Pollard, Dan M Granoff
MenB-4C is a meningococcal vaccine for the prevention of serogroup B disease. The vaccine contains factor H binding protein (FHbp) and three other antigens that can elicit serum bactericidal antibodies (SBA). For vaccine licensure, efficacy was inferred from the SBA responses against three antigen-specific indicator strains. The relation between those results and broad protection against circulating genetically diverse strains is not known. Twenty adults were immunized with two doses of MenB-4C given 1 to 2 months apart...
January 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/27846061/neisseria-meningitidis-serogroup-b-vaccine-bivalent-rlp2086-induces-broad-serum-bactericidal-activity-against-diverse-invasive-disease-strains-including-outbreak-strains
#18
Shannon L Harris, Robert G K Donald, Julio Cesar Hawkins, Cuiwen Tan, Robert O'Neill, Lisa K McNeil, John L Perez, Annaliesa S Anderson, Kathrin U Jansen, Thomas R Jones
BACKGROUND: Bivalent rLP2086 (Trumenba®), 1 of 2 meningococcal serogroup B (MnB) vaccines recently approved in the United States for prevention of MnB disease in individuals aged 10-25 years, is composed of 2 lipidated factor H binding proteins (fHBPs) from subfamilies A and B. This study evaluated the breadth of MnB strain coverage elicited by bivalent rLP2086 measured with serum bactericidal assays using human complement (hSBAs). METHODS: hSBA responses to diverse MnB clinical strains circulating in the United States and Europe (n=23), as well as recent US university outbreak strains (n=4), were evaluated...
November 11, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27832151/nationwide-trends-in-bacterial-meningitis-before-the-introduction-of-13-valent-pneumococcal-conjugate-vaccine-burkina-faso-2011-2013
#19
Dinanibè Kambiré, Heidi M Soeters, Rasmata Ouédraogo-Traoré, Isaïe Medah, Lassana Sangare, Issaka Yaméogo, Guetawendé Sawadogo, Abdoul-Salam Ouédraogo, Soumeya Hema-Ouangraoua, Lesley McGee, Velusamy Srinivasan, Flavien Aké, Malika Congo-Ouédraogo, Soufian Sanou, Absatou Ky Ba, Ryan T Novak, Chris Van Beneden
BACKGROUND: Following introduction of Haemophilus influenzae type b vaccine in 2006 and serogroup A meningococcal conjugate vaccine in 2010, Streptococcus pneumoniae (Sp) became the leading cause of bacterial meningitis in Burkina Faso. We describe bacterial meningitis epidemiology, focusing on pneumococcal meningitis, before 13-valent pneumococcal conjugate vaccine (PCV13) introduction in the pediatric routine immunization program in October 2013. METHODS: Nationwide population-based meningitis surveillance collects case-level demographic and clinical information and cerebrospinal fluid (CSF) laboratory results...
2016: PloS One
https://www.readbyqxmd.com/read/27817957/long-term-persistence-of-protective-antibodies-in-dutch-adolescents-following-a-meningococcal-serogroup-c-tetanus-booster-vaccination
#20
Mariëtte B van Ravenhorst, Axel Bonacic Marinovic, Fiona R M van der Klis, Debbie M van Rooijen, Marjan van Maurik, Susanne P Stoof, Elisabeth A M Sanders, Guy A M Berbers
INTRODUCTION: Due to waning immunity, infant vaccination with meningococcal serogroup C conjugated (MenCC) vaccines is insufficient to maintain long-term individual protection. Adolescent booster vaccination is thought to offer direct protection against invasive meningococcal disease (IMD) but also to reduce meningococcal carriage and transmission and in this way establish herd protection in the population. Previously, we studied antibody levels after adolescent MenCC booster vaccination...
December 7, 2016: Vaccine
keyword
keyword
61786
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"